Connect with us

Media & Technology

Optec International Inc (OTCMKTS: OPTI) Revnues PPE Deal, and Up-Listing

Published

on

Optec International Inc (OTCMKTS: OPTI) is the penny stock runner that skyrocketed to highs of $0.195 earlier this year and speculators are patiently waiting for a return to these highs in the face of big things happening for OPTI. In a recent update to shareholders, management stated: “We plan on up-listing to the QB in the beginning of Q1 and have already started the process. Based on our current growth, we anticipate the Company will be preparing for an up-list to the Nasdaq at some point in the later part of 2021 or early 2022 as we currently meet many of the requirements for that exchange. Optec also expects that revenues will continue to exceed all expectations as several other large PPE deal are going to be completed in 2021.”

OPTI emerged as the penny stock leader in PPE when the Company reported it secured a $2 billion agreement with a large International Commodities Consortium for the supply of Brand Specific Personal Protection Equipment (PPE) products. Optec said it is finalizing the logistics portion of the order and is anticipating completion by the end of the month. Kevin Harrington and his group will also be launching a social media campaign marketing the iWand to their network and beyond. This campaign coupled with the promotional billboards around Los Angeles will continue to increase market awareness for this product.

Optec International Inc (OTCMKTS: OPTI) with Locations in Carlsbad and Vista, California, OPTEC International is a developer and manufacturer of electronic LED, Ultraviolet (UV) & UV-C safety products and related advanced technologies and PPE (Personal Protection Equipment) products. The company’s Safe-Scan product line is being launched at a time when HR directors and facilities managers are experiencing extreme concern with respect to keeping environments safe during the global pandemic crisis and the safe reopening of the U.S. economy.

OPTI was one of the first Company’s to make moves in the coronavirus space as the deadly virus spreads around the world. Long before corona came along Optec had already perfect its high quality (Ultra-Violet) UV-C & UV Germicidal Non-Toxic Sanitization and Disinfection using Chemical Free technologies and products. The Company launched a number of exciting products into the space some that have been extremely successful such as the iWand; a portable UV-C LED disinfection device that Kills 99.99% of bacteria, viruses, and other contaminants on any surface in seconds. Optec has also executed a number of large wholesale transaction quantities of 3M KN 95 masks and other PPE equipment. Optec recently executed a definitive agreement for the supply of Brand Specific Personal Protection Equipment (PPE) products for a large International Commodities Consortium totaling in excess of $2 Billion Dollars US.

On December 9 OPTI management stated to shareholders: “I would like to start by thanking each and every one of our shareholders for their continued support of Optec International, Inc. I am pleased to report to you on our 2020 year to date progress and share our outlook for the balance of the year. The Company has grown tremendously over the year as evidenced by the increase in revenues, and we believe we are well positioned to continue to deliver value for our shareholders. Some of the developments we would like to highlight and update the shareholders on include:

We closed a $5,000,000 funding deal with RB Capital Partners, Inc., creating a solid financial foundation for growth in the coming year. As of today, RB Capital has funded $4,600,000 of the $5,000,000 deal with Optec. The primary use of funds has been for the iWandä production and distribution in addition to financing the PPE deal. The funding partnership not only signifies the support of a long-term financial partner, but also indicates that we have paid off all other harmful debt. The investment money provided by RB Capital is completely non-toxic, non-dilutive and is in the best interest of the Company and the shareholders as the it has a fixed conversion price of $0.70 per share.

To Find out the inside Scoop on OPTI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

OPTI

The company is finalizing the logistics portion of the recent $2B PPE purchase order and is anticipating completion by the end of the month. It is expected that the revenue portion of this transaction will be reported on the December 31, 2020 quarterly report.

We surpassed our previous quarter’s income and revenue by over 600% for the period ending September 30, 2020. The Company surpassed its $4,000,000 projection for the quarter ending September 30th and, in fact, showed revenue and income totaling $6,284,609 and a net income of $3,381,730. In addition, the Company has paid in full all previous convertible institutional notes and the interest and liabilities associated with those notes. We project an increase in revenue over last quarter for Q4.

Optec appoints Dr. Drew Pinsky, nationally known television, radio, and podcasting host and New York Times bestselling author as Brand Ambassador. Dr. Drew will help to open up increased distribution opportunities. We announced a new agreement with Vinco Ventures, Inc.

We have successfully launched our Touchless Safe- Scanners and Rovers within several different school districts. To date, we have implemented our Touchless Safe-Scanners and Rovers to both local and nationwide school districts. It remains to be seen when all schools will be given the green light to fully re-open, but we have strong relationships with several school districts around the country to be able to ship more product and enable a safe re-open when allowed.

The Harrington Group is launching a nation-wide Campaign for the iWandä. Kevin Harrington and his group will be launching their own social media campaign marketing the iWandä to their network and beyond. This campaign coupled with the promotional billboards around Los Angeles will continue to increase market awareness for this product.

Forecast and Outlook for 2021. We plan on uplisting to the QB in the beginning of Q1 and have already started the process. We also plan on applying for Penny Stock Exempt status as we will soon meet the criteria. Based on our current growth, we anticipate the Company will be preparing for an uplist to the Nasdaq at some point in the later part of 2021 or early 2022 as we currently meet many of the requirements for that exchange. Optec also expects that revenues will continue to exceed all expectations as several other large PPE deal are going to be completed in 2021.

https://twitter.com/B3342716919/status/1337092479389200388

For More on OPTI Subscribe Right Now

OPTI is one of the most exciting stories in small caps that has gained serious traction in the face of coronavirus. Long before corona came along Optec had already perfected its high quality (Ultra-Violet) UV-C & UV Germicidal Non-Toxic Sanitization and Disinfection using Chemical Free technologies and products.  In a recent update to shareholders, management stated: “We plan on up-listing to the QB in the beginning of Q1 and have already started the process. Based on our current growth, we anticipate the Company will be preparing for an up-list to the Nasdaq at some point in the later part of 2021 or early 2022 as we currently meet many of the requirements for that exchange. Optec also expects that revenues will continue to exceed all expectations as several other large PPE deal are going to be completed in 2021.” OPTI emerged as the penny stock leader in PPE when the Company reported it secured a $2 billion agreement with a large International Commodities Consortium for the supply of Brand Specific Personal Protection Equipment (PPE) products. Optec said it is finalizing the logistics portion of the order and is anticipating completion by the end of the month. Kevin Harrington and his group will also be launching a social media campaign marketing the iWand to their network and beyond. We will be updating on OPTI when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with OPTI.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in OPTI either long or short and we have not been compensated for this article.

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.